The effect of valsartan on the angiotensin II pressor response in healthy normotensive male subjects

What Was Tested

The paper reports a study of Angiotensin II, published as a randomized controlled trial.

Valsartan is an oral antagonist of angiotensin II that competes with angiotensin II for the AT1-receptor and is being developed as an antihypertensive agent.

Who Took Part

By PubMed's age tags, the people studied were adults, men only.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and crossover.

Random assignment meant chance, not the researchers, decided who got Angiotensin II and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Angiotensin II, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Angiotensin II could be set against what happens without it.

Each person switched between Angiotensin II and the comparison at some point, usually with a gap in between.

This was a single-center, double-blind, placebo-controlled, randomized crossover study.

The inhibition of the angiotensin II pressor effect was determined by the systolic blood pressure response to repeated angiotensin II challenges at multiple time points.

What Was Measured

Topics PubMed links to this paper include Analysis of Variance, Angiotensin II, Angiotensin Receptor Antagonists, Antihypertensive Agents, Area Under Curve, Blood Pressure and Linear Models.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Angiotensin II.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1997 (Clinical pharmacology and therapeutics), a journal based in United States.

More context: the Angiotensin II compound page, all human trials.